Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical Officer

Neuromuscular Expert Joins as Company Prepares Lead Muscular Dystrophy Product Candidate for Clinical Development

Boulder, Colo., (June 17, 2020)  Edgewise Therapeutics, a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of Kirsten L. Gruis, M.D., M.S. to the newly created position of Chief Medical Officer.  Dr. Gruis will be responsible for leading clinical, medical and regulatory strategy and operations for the drug pipeline, including EDG-5506, the company’s lead product candidate that is being prepared for clinical development for Duchenne and Becker muscular dystrophy (DMD and BMD).  Dr. Gruis brings a wealth of experience in neuromuscular drug development, following a successful track record of leadership positions at innovative biopharmaceutical and pharmaceutical companies, including Roche, Agilis Biotherapeutics (acquired by PTC Therapeutics), WAVE Life Sciences, Alnylam Pharmaceuticals and Pfizer.  Most recently at Roche, Dr. Gruis was the Global Head of the neuromuscular franchise, leading the development of spinal muscular atrophy (SMA) and DMD therapeutics, including risdiplam, an investigational SMN-2 splicing modifier for SMA, which is currently under Priority Review with the U.S. Food and Drug Administration.

“We are thrilled that Dr. Gruis has joined our management team, bringing a wealth of industry and medical leadership as we prepare EDG-5506 for clinical development,” said Kevin Koch, Ph.D., President and Chief Executive Officer, Edgewise Therapeutics. “Dr. Gruis has deep experience in neuromuscular drug development, which will be valuable as we execute our clinical, medical and regulatory strategies.”

Find out more in the press release.

Categories: Ecosystem News